Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study

被引：0
|
作者：
Ralf Gold
Ernst-Wilhelm Radue
Gavin Giovannoni
Krzysztof Selmaj
Eva Kubala Havrdova
Xavier Montalban
Dusan Stefoski
Till Sprenger
Randy R. Robinson
Sami Fam
Jonathan Smith
Spyros Chalkias
Giorgio Giannattasio
Gabriel Lima
Wanda Castro-Borrero
机构：
[1] St. Josef-Hospital/Ruhr-University Bochum,Medical Image Analysis Center
[2] University Hospital Basel,Barts and The London School of Medicine and Dentistry
[3] Queen Mary University of London,Department of Neurology
[4] University of Warmia and Mazury,Department of Neurology, First Faculty of Medicine
[5] Charles University,undefined
[6] Hospital Vall d’Hebron University,undefined
[7] Rush University Medical Center,undefined
[8] DKD Helios Klinik Wiesbaden,undefined
[9] AbbVie Inc.,undefined
[10] Biogen,undefined
[11] Biogen,undefined
来源：
Journal of Neurology | 2020年 / 267卷
关键词：
Daclizumab beta; Relapsing–remitting multiple sclerosis; SELECTED; Clinical trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2851 / 2864
页数：13
相关论文
共 50 条
  • [31] Long-term efficacy and safety of ponesimod: results from randomized phase ii core and extension studies in relapsing-remitting multiple sclerosis
    Freedman, M.
    Pozzilli, C.
    Havrdova, E. Kubala
    Coyle, P.
    Lemle, A.
    Burcklen, M.
    Larbalestier, A.
    Hennessy, B.
    Scherz, T.
    Vaclavkova, A.
    Olsson, T.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 222 - 222
  • [32] LONG-TERM EFFICACY OF LANADELUMAB: INTERIM RESULTS FROM THE HELP OPEN-LABEL EXTENSION STUDY
    Riedl, M.
    Cicardi, M.
    Hao, J.
    Lu, P.
    Li, H.
    Manning, M.
    Bernstein, J.
    Busse, P.
    Tachdjian, R.
    Gower, R.
    Wedner, H.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 123 (05) : S30 - S31
  • [33] Long-term efficacy of fingolimod in patients with relapsing remitting multiple sclerosis: results from the phase 3 FREEDOMS II extension study
    Reder, A. T.
    Jeffery, D.
    Goodin, D.
    Kappos, L.
    Lublin, F. D.
    Radue, E. W.
    Rammohan, K.
    Vollmer, T.
    Agius, M. A.
    Stites, T.
    Li, B.
    Cappiello, L.
    von Rosenstiel, P.
    Calabresi, P. A.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 510 - 511
  • [34] Safety and Clinical Efficacy Outcomes from the Long-term Extension Study of Tolebrutinib in Participants with Relapsing Multiple Sclerosis: 3-Year Results
    Oh, Jiwon
    Reich, Daniel
    Traboulsee, Anthony
    Arnold, Douglas L.
    Syed, Sana
    Dukovic, Deborah
    Vargas, Wendy S.
    Turner, Timothy
    Fox, Robert J.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 334 - 335
  • [35] EFFICACY AND SAFETY OF LONG-TERM TREATMENT WITH LURASIDONE IN ADOLESCENTS WITH SCHIZOPHRENIA: RESULTS OF A 2-YEAR, OPEN-LABEL EXTENSION STUDY
    Correll, C.
    Goldman, R.
    Tocco, M.
    Pikalov, A.
    Deng, L.
    Loebel, A.
    Coghill, D.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2019, 53 : 105 - 105
  • [36] EVOLVE-MS-1: Phase 3 Open-Label Long-Term Safety Study of ALKS 8700 in Relapsing-Remitting Multiple Sclerosis
    Naismith, Robert
    Leigh-Pemberton, Richard
    Claxton, Amy
    Du, Yangchun
    Hard, Marjie
    von Moltke, Lisa
    Wolinsky, Jerry
    NEUROLOGY, 2017, 88
  • [37] EVOLVE-MS-1: a phase 3, open-label, long-term safety study of ALKS 8700 in relapsing-remitting multiple sclerosis
    Naismith, R. T.
    Leigh-Pemberton, R. A.
    Rezendes, D.
    Ge, T.
    von Moltke, L.
    Wolinsky, J. S.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 617 - 617
  • [38] Safety and Clinical Efficacy Outcomes From the Long-term Extension Study of Tolebrutinib in Participants With Relapsing Multiple Sclerosis: 2.5-Year Results
    Oh, Jiwon
    Syed, Sana
    Li, Tong
    Salloum, Naji
    Turner, Timothy J.
    Fox, Robert J.
    NEUROLOGY, 2023, 100 (17)
  • [39] Safety and clinical efficacy outcomes from the Long-term extension study of tolebrutinib in patients with relapsing multiple sclerosis: 2-year results
    Oh, J.
    Syed, S.
    Orogun, L.
    Xu, Z.
    Turner, T. J.
    Fox, R. J.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 342 - 343
  • [40] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial
    Cree, Bruce A. C.
    Selmaj, Krzysztof W.
    Steinman, Lawrence
    Comi, Giancarlo
    Bar-Or, Amit
    Arnold, Douglas L.
    Hartung, Hans-Peter
    Montalban, Xavier
    Havrdova, Eva K.
    Sheffield, James K.
    Minton, Neil
    Cheng, Chun-Yen
    Silva, Diego
    Kappos, Ludwig
    Cohen, Jeffrey A.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (12) : 1944 - 1962
12345